Why the study?
Does high estimated RLP-C level predict recurrent adverse events in patients with diabetes and NSTE-ACS treated with PCI?
Does high estimated RLP-C level predict recurrent adverse events in patients with diabetes and NSTE-ACS treated with PCI?
Estimated RLP-C levels can serve as a prognostic marker for recurrent adverse events in diabetic patients with NSTE-ACS undergoing PCI.
No takes yet. Share an insight, caveat, or question.
May support RLP-C for risk stratification in diabetic NSTE-ACS post-PCI; leaves open prospective validation before practice change.
Zhao et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: